OTCM
CHGCY
Market cap70bUSD
Sep 17, Last price
21.40USD
1D
-1.15%
1Q
-12.37%
Jan 2017
316.07%
Name
Chugai Pharmaceutical Co Ltd
Chart & performance
P/E
25.31
P/S
8.73
EPS
263.71
Div yield, %
4.14%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
9.84%
Revenues
1.26t
+7.46%
Net income
434.01b
+12.06%
CFO
389.45b
-12.99%
Dividend
Dec 29, 20260.21121 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
Key people
Toshiaki Itagaki
Chief Financial Officer, Senior Executive Officer, Director of Finance & Accounting, Senior Manager of Finance · since 2017
Junichi Ebihara
Senior Executive Officer, Director of Legal Affairs · since 2017
Yasushi Ito
Senior Executive Officer, Co-Manager of Project & Lifecycle Management Unit · since 2017
Susumu Kato
Senior Executive Officer · since 2017
Mitsuru Kikuchi
Senior Executive Officer · since 2016
Keiji Kono
Senior Executive Officer · since 2017
Yoshiaki Ohashi
Senior Executive Officer, Chief Director of Drug Safety, Manager of Regulatory & Quality Assurance Unit · since 2018
Hisafumi Okabe
Senior Executive Officer, Chief Director of Translational Clinical Research · since 2017
Shinya Unno
Senior Executive Officer, Senior Manager of Human Resources · since 2016
Koichi Nishikawa
Executive Officer, Deputy Chief Director of Sales, Director of Overseas Sales Promotion · since 2017
Shinji Hidaka
Executive Officer, Chief Director of Medical Affairs · since 2017
Toshihiko Komori
Executive Officer · since 2017
Hiroyuki Matsumoto
Executive Officer, Senior Manager of South Kanto Office in Main Sales Unit · since 2017
Hiroshi Murata
Executive Officer, Chief Director of Pharmaceutical Technology · since 2017
Kaori Ohuchi
Executive Officer, Chief Director of Medical Affairs, Director of Medical Science
Hisanori Takanashi
Executive Officer, Chief Director of Clinical Development · since 2017
Minoru Watanabe
Executive Officer, Manager of Project Lifecycle Management Unit · since 2019
Tetsuya Yamaguchi
Executive Officer, Director of Business Development · since 2017
Director · since 2019
Mariko Momoi
Independent Director · since 2020
Headquarters & legal address
北区浮間５丁目５番１号
東京都, 13 115-0051
JP
東京都, 13 115-0051
JP
Other language
Chugai Pharmaceutical Co., Ltd.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||